Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 5/20 | 0.45 |
| ▸ | KDM4A | O75164 | 2/20 | 0.45 |
| ▸ | KDM4B | O94953 | 2/20 | 0.45 |
| ▸ | KDM5C | P41229 | 2/20 | 0.45 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.45 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.45 |
| ▸ | CLK1 | P49759 | 3/20 | 0.37 |
| ▸ | ACHE | P22303 | 2/20 | 0.37 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.35 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.35 |
| ▸ | NFATC1 | O95644 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | LATS1 | O95835 | 2/20 | 0.34 |
| ▸ | LATS2 | Q9NRM7 | 2/20 | 0.34 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.34 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4378158 | 0.88 | CLK1 (0.40) | KDM4CKDM4AKDM4BKDM5CKDM5B | |
| SCHEMBL29694218 | 0.79 | TLR7 (0.44) | ACHEPDPK1LMNA | |
| SCHEMBL212131 | 0.79 | TLR7 (0.44) | ACHEPDPK1LMNA | |
| Hydrochloric Acid SCHEMBL5523405 | 0.78 | RAB9A (0.44) | ACHEPDPK1LMNA | |
| SCHEMBL3516564 | 0.77 | QPCT (0.50) | CDK5DYRK1AGSK3BTBK1 | |
| Hydrochloric Acid SCHEMBL10587438 | 0.76 | ALDH1A1 (0.46) | ACHEPDPK1LMNA | |
| SCHEMBL28312743 | 0.75 | TLR7 (0.44) | ACHELMNA | |
| SCHEMBL2113965 | 0.74 | PTGES (0.44) | CLK1ACHECDK5CDK5R1DYRK1A | |
| SCHEMBL17969621 | 0.73 | KDM4A (0.44) | KDM4CKDM4AKDM4BKDM5CKDM5B | |
| SCHEMBL12733974 | 0.72 | CLK1 (0.46) | KDM4CCLK1ACHECDK5CDK5R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8778963-B2 | Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-07-15 | — | — | US | disclosed |
| US-8329721-B2 | Hydroxy and alkoxy substituted 1H-imidazonaphthyridines and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-12-11 | — | — | US | disclosed |
| US-7678918-B2 | Intermediates for imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2010-03-16 | — | — | US | disclosed |
| US-20090298821-A1 | HYDROXY AND ALKOXY SUBSTITUTED IH-IMIDAZONAPHTHYRIDINES AND METHODS | PFIZER INC. | 2009-12-03 | — | — | US | disclosed |
| US-20080091010-A1 | Intermediates for imidazonaphthyridines | GRACEWAY PHARMACEUTICALS, LLC (US) | 2008-04-17 | — | — | US | disclosed |
| US-7335773-B2 | Intermediates for imidazonaphthyridines | GRACEWAY PHARMACEUTICALS, LLC (US) | 2008-02-26 | — | — | US | disclosed |
| WO-2007106854-A2 | HYDROXY AND ALKOXY SUBSTITUTED 1H-IMIDAZONAPHTHYRIDINES AND METHODS | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2007-09-20 | — | — | WO | disclosed |
| US-20070167481-A1 | IMIDAZONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY | 2007-07-19 | — | — | US | disclosed |
| US-20070099901-A1 | Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-05-03 | — | — | US | disclosed |
| EP-1686992-A2 | HYDROXYLAMINE AND OXIME SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES | 3M Innovative Properties Company (US) | 2006-08-09 | — | — | EP | disclosed |
| US-20040006098-A1 | INDUCE CYTOKINE BIOSYNTHESIS IN ANIMALS | 3M INNOVATIVE PROPERTIES COMPANY | 2004-01-08 | — | — | US | disclosed |
| US-20030212093-A1 | Viricides, antitumor agents | 3M INNOVATIVE PROPERTIES COMPANY | 2003-11-13 | — | — | US | disclosed |
| US-6624172-B2 | Imidazonaphthyridine and tetrahydroimidazonaphthyridine compounds induce the biosynthesis of cytokines such as interferon and tumor necrosis factor, and useful as viricides and antitumor agents | 3M INNOVATIVE PROPERTIES COMPANY | 2003-09-23 | — | — | US | disclosed |
| US-20030096998-A1 | Imidazonaphtyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-05-22 | — | — | US | disclosed |
| US-20030083500-A1 | Imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-05-01 | — | — | US | disclosed |
| US-6518280-B2 | Antiviral and antitumor properties; immunomodulators and for inducing cytokine biosynthesis in animals | 3M INNOVATIVE PROPERTIES COMPANY | 2003-02-11 | — | — | US | disclosed |
| US-6514985-B1 | Induce the biosynthesis of cytokines such as interferon and tumor necrosis factor; exhibit antiviral and antitumor properties | 3M INNOVATIVE PROPERTIES COMPANY | 2003-02-04 | — | — | US | disclosed |
| US-20020173654-A1 | Imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2002-11-21 | — | — | US | disclosed |
| US-20020173653-A1 | Imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2002-11-21 | — | — | US | disclosed |
| US-6194425-B1 | VIRICIDES, ANTITUMOR AGENTS | 3M INNOVATIVE PROPERTIES COMPANY | 2001-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080091010-A1 | Intermediates for imidazonaphthyridines | IFNG, IRF3, MAVS | KDM4C 4385/4885KDM4A 4354/4885KDM4B 4586/4885 |
| US-20030083500-A1 | Imidazonaphthyridines | IFNG, IRF3, IFNAR1 | KDM4C 4340/4885KDM4A 4129/4885KDM4B 4473/4885 |
| US-20090298821-A1 | HYDROXY AND ALKOXY SUBSTITUTED IH-IMIDAZONAPHTHYRIDINES AND METHODS | IL2, IL4, IFNG | KDM4C 1514/4885KDM4A 2134/4885KDM4B 2669/4885 |
| US-20030096998-A1 | Imidazonaphtyridines | IFNG, IRF3, IFNAR1 | KDM4C 4373/4885KDM4A 4179/4885KDM4B 4507/4885 |
| US-20040006098-A1 | INDUCE CYTOKINE BIOSYNTHESIS IN ANIMALS | IFNG, IFNAR1, EIF2AK2 | KDM4C 4268/4885KDM4A 3952/4885KDM4B 4478/4885 |
| US-20070167481-A1 | IMIDAZONAPHTHYRIDINES | IFNG, IRF3, IFNAR1 | KDM4C 4340/4885KDM4A 4129/4885KDM4B 4473/4885 |
| US-20070099901-A1 | Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines | IFNG, IRF3, IDO1 | KDM4C 1121/4885KDM4A 737/4885KDM4B 1319/4885 |
| US-20020173653-A1 | Imidazonaphthyridines | IFNG, IRF3, IFNAR1 | KDM4C 4340/4885KDM4A 4129/4885KDM4B 4473/4885 |
| US-20020173654-A1 | Imidazonaphthyridines | IFNG, IRF3, IFNAR1 | KDM4C 4340/4885KDM4A 4129/4885KDM4B 4473/4885 |
| US-20030212093-A1 | Viricides, antitumor agents | IFNG, IFNAR1, MAVS | KDM4C 4495/4885KDM4A 4302/4885KDM4B 4615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.